There is a global increase in the prevalence of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) in Australia and New Zealand. Risk factors for HPV-positive OPSCC are male gender, white race, age older than 40 but younger than 59 years old, having multiple lifetime sex partners, having oro-genital and oro-anal sex. High-risk HPV subtypes play a major role in the pathogenesis of OPSCC, however, they play a much lesser role in oral squamous cell carcinoma (OSCC). Among the laboratory tests used to detect oncogenic HPV infection, polymerase chain reaction is a sensitive method but does not reflect the role of HPV in oncogenesis. While widely used, p16 immunohistochemistry is both a sensitive and a specific surrogate marker for oncogenic HPV infection in OPSCC, but not in OSCC. However, it is a useful prognostic marker in OPSCC. The current gold standard to accurately detect oncogenic HPV infection is E6/E7 mRNA in situ hybridization. Because both HPV-positive and p16-positive OPSCC have better shortterm prognoses there is current debate and trials on treatment de-escalation in HPV-positive OPSCC. Dental practitioners can play an important role in early diagnosis of HPV-positive OPSCC.
INTRODUCTION
Oral cancer usually refers to squamous malignancies of the oral mucosa and lip vermilion but the term is used variably. In some publications, it is used to describe cancers of the oral and oropharyngeal regions, including salivary gland and connective tissue malignancies. 1 On the other hand, head and neck cancers include cancers of the oral cavity, pharynx, larynx, paranasal sinuses, thyroid and salivary glands and their supporting hard and soft tissue. The majority of these cancers are squamous cell carcinomas (SCC) which are referred to as head and neck squamous cell carcinoma (HNSCC). Similarly, approximately 90% of cancers arising in the oral cavity and lip vermilion -excluding the skin of the lips and oropharynx, are SCC and are referred to as oral squamous cell carcinoma (OSCC) in this paper.
Recently, a steep rise in the global incidence of oropharyngeal squamous cell carcinoma (OPSCC) in males has been reported. 2 For example, a 225% increase in the prevalence of HPV-positive OPSCC was reported in the United States from 1984 to 2004. 2 Similar trends have been reported in Australia and New Zealand. [3] [4] [5] In Australia, Hong and colleagues reported more than three-fold rise in the percentage of HPV-positive OPSCC in the last two decades from 20% to more than 63%. 5 Due to the association of HPV infection with a subset of HNSCC, there has been interest in the role of the human papillomavirus (HPV) in the pathogenesis of HNSCC as well as diagnostic laboratory tests to detect these cancers and prognostic biomarkers.
With regard to risk factors, tobacco and alcohol consumption account for more than 75% of OSCC whereas high-risk HPV types account for a very small proportion (1-3%). [6] [7] [8] [9] [10] Betel quid use, with or without tobacco, is also an established risk factor for OSCC and OPSCC, particularly in the Indian subcontinent. 11, 12 Ultraviolet radiation is the major aetiological factor in lip vermilion and skin SCCs, particularly in fair-skinned individuals. 13 On the other hand, high- This article addresses the main issues that need to be considered in the interpretation and clinical application of p16 immunohistochemistry (IHC) and other tests for the detection of oncogenic HPV infection in OSCC and OPSCC, planning treatment including chemotherapy and radiotherapy and predicting prognosis in OPSCC.
Epidemiology and risk factors
According to a systematic review and meta-analysis of articles published until early 2013, the global pooled estimate of OPSCC attributable to high-risk HPV was close to 40%. 15 The estimated global HPV16 subtype prevalence in OSCC is 14.9% whereas that in OPSCC is 40.6%. On the other hand, the estimates for HPV18 subtype are 5.9% in OSCC and 0.2% in OPSCC. 15 However, the authors concluded that data regarding the confounding effect of tobacco and alcohol use is limited. 15 The role of high-risk HPV in the pathogenesis of OPSCC is established. However, it plays a much lesser role in the pathogenesis of OSCC. 8, 14, 17 Although many of the malignancies arising in the oropharynx are SCC, they have distinct aetiopathological features.
Recent studies in Australia and New Zealand have shown that OPSCCs harboured high-risk HPV subtypes in 220 of 519 (42%) and 41 of 55 (75%) patients, respectively. 5, 18 It must be noted that 27 of the 41 patients were either ex-smokers or current smokers and all 41 were alcohol drinkers in the New Zealand study, 18 whereas 161 of the 220 patients (73%) were either smokers or ex-smokers and 152 of the 220 patients (69%) were either alcohol drinkers or ex-drinkers in the Australian study. 5 In the remaining 36 of 220 patients (16%) whose OPSCC harboured high-risk HPV, the alcohol drinking status was unknown. 5 The risk indicators for high-risk HPV infection of the oral cavity and oropharynx are male gender, white race, age older than 40 but younger than 59 years old, having multiple lifetime sex partners, having orogenital and oro-anal sex.
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Anatomical site: oral vs. oropharyngeal
The oral mucosa includes the non-keratinized labial mucosa, buccal mucosa, vestibular mucosa, ventral surface of the tongue, and the floor of the mouth in addition to the keratinized two-thirds of the dorsum of the tongue, hard palate and gingivae, while the oropharynx is the part of the pharynx that comprises the soft palate, pillars of the fauces, palatine tonsils, uvula, posterior one-third or base of the tongue and the lateral and posterior walls of the pharynx (Fig. 1A-C) . However, as it can be seen in Table 1,   22 the International Classification of Diseases for Oncology (ICD-O) oropharyngeal topographic sub-site codes are found under several major site codes such as the base of the tongue (C01), other and unspecified parts of the tongue (C02), palate (C05), tonsil (C09), oropharynx (C10), and other ill-defined sites in lip, oral cavity and pharynx (C14). Therefore, care should be taken to carefully document the precise site of the cancer for appropriate topographic classification.
The role of human papillomavirus in the pathogenesis of oral and oropharyngeal cancers HPV is a double-stranded DNA virus that is implicated in many common, mostly benign/hyperplastic, oral lesions. An example is squamous cell papilloma that appears as a cauliflower-like pedunculated growth and is one of the most common mucosal lesions submitted to histopathology diagnostic services. 23 Low-risk HPV subtypes are implicated in these benign lesions, whereas high-risk HPV subtypes are those implicated in carcinogenesis and are hence termed oncogenic. These include most notably HPV16 and HPV18. 24 HPV16 subtype has been categorized by the IARC as a risk factor with sufficient evidence to support its role in the pathogenesis of both OPSCC and OSCC. 16 On the other hand, HPV18 subtype is listed as an agent with limited evidence in humans for OSCC due to limited evidence supporting its role in the pathogenesis of OSCC but it is not listed as a risk factor for OPSCC. 16 For an HPV infection to be deemed oncogenic, viral E6 and E7 mRNA should be detected. These genes encode for oncoproteins and are produced as a result of integration of the viral genome into the host cell DNA. Their detection is essential to enable accurate identification of transcriptionally active oncogenic HPV infection in OPSCC and OSCC.
25 E6 oncoprotein degrades p53 tumour suppressor protein whereas E7 inactivates retinoblastoma (Rb) tumour suppressor protein. Once Rb is inactivated, it releases E2F which potentiates the transcription of genes related to S phase progression ( Figure 2 ). In addition, E6 and E7 bring about the aberrant expression of telomerase,
thereby delimiting the cells' replicative capacity and leading to immortalization. 24 
Clinicopathological characteristics of OPSCC associated with high-risk HPV (OPSCC-HPV)
OPSCC-HPV affects a relatively younger age group than conventional OPSCC. 26 The risk factors of tobacco and alcohol consumption are usually present but found in a relatively lesser proportion than in those with conventional OPSCC. 26 It is important to note that in OPSCC-HPV, lymph node metastasis is an early event and often the primary presenting feature. Therefore, it is imperative that clinicians regularly and carefully examine their patients for lymph node enlargement and investigate or refer suspicious cases accordingly. On the other hand, distant metastases can occur up to 10 years of initial diagnosis which makes long-term follow-up an important issue. 26 The advantage of comprehensive and thorough intra-and extra-oral examination cannot be over-emphasized, especially by oral healthcare professionals who are in an excellent position to screen for and detect OPSCC. It is understandable that the examination of the entire oropharynx by dental practitioners is difficult. However, dentists are able to examine the soft palate, uvula, the palatine tonsils, the pillars of the fauces, and to a certain extent the posterior one-third of the tongue (Fig. 1C) . In their paper, Mighell and Gallagher provide an excellent clinical example which shows the importance of comprehensive intra-oral examination to detect OPSCC. 27 Histologically, most OPSCC-HPV are non-keratinizing. They sometimes have a papillary architecture and the malignant cells have basaloid features. Although OPSCC-HPVs have been regarded as poorly differentiated based on the aforementioned features; they are likely well-differentiated as they closely resemble the reticulated tonsillar crypt epithelium from which they are derived. Moreover, these should not be confused with the aggressive basaloid variant of SCC. 28 In terms of prognosis, OPSCC-HPVs have higher short-term survival rates than HPV-negative HPV, OSCC, and OPSCC: the essentials OPSCC. 26, 29 However, the long-term survival is currently a matter of debate due to the emergence of late distant metastases when the patients have the conventional risk factors of tobacco and alcohol consumption. 26 Overall, in the absence of the conventional risk factors of tobacco and alcohol, OPSCC-HPV responds more favourably to chemotherapy and radiotherapy, possibly due to the relatively intact DNA repair and tumour-suppressor mechanisms. Fig. 2 The effects of oncogenic HPV infection on cell-cycle control. (1) E7 leads to hyperproliferation by inhibiting the association of pRb with E2F, and thereby freeing E2F which potentiates the transcription of genes related to S phase progression. (2) E6 inhibits p53 by ubiquitination leading to the degradation of p53, resulting in the avoidance of growth arrest and apoptosis, allowing cells to passage through G1 to S phase. (3) p16 is overexpressed in response to p53 degradation and Rb repression. The p16 inhibits CKDs 2, 4 and 6, thereby preventing phosphorylation of Rb, which is required for S phase entry.
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Laboratory tests to detect oncogenic HPV infection
Oncogenic HPV infection can be detected using several methods at the DNA, mRNA, or protein levels ( Table 2) . HPV DNA can be detected using polymerase chain reaction (PCR) or DNA in situ hybridization (ISH) on tissue sections. These methods have been used to detect viral DNA by many of the studies that have attempted to investigate the role of oncogenic HPV infection in OSCC and OPSCC. Conventional PCR is an extremely sensitive method, but it only yields a 'positive' or 'negative' result and the viral genome can be detected without having contributed to carcinogenesis. On the other hand, quantitative PCR (qPCR) can be used to detect the relative quantity of high-risk HPV DNA and reflect their oncogenic role. 25, 31, 32 Several of the earlier and even recent papers including meta-analyses investigating the prevalence of OPSCC-HPV have used PCR, or p16 IHC as a surrogate marker, for detection of highrisk HPV, which has resulted in an overestimation of the true fraction of OPSCC-HPV. 2, 33 To detect the products of viral integration into the host genome; PCR, quantitative PCR, or E6/E7 mRNA ISH can be performed. The advantage of qPCR is that the results can give an indication of the quantity of viral E6/E7 mRNA relative to control genes and can better detect biologically relevant oncogenic HPV infection. In addition, E6/E7 mRNA ISH can be carried out on tissue sections, and is considered the current gold standard in detecting OPSCC-HPV. 25, 34 However, p16 IHC is an easy and affordable way to help detect oncogenic HPV infection in OPSCC. p16 is a tumour suppressor protein that inhibits the progression of the cell cycle through the inhibition of a cyclin-dependent kinase, which is why it is known as a cyclin-dependent kinase inhibitor. In oncogenic HPV infection, p16 is overexpressed in response to p53 degradation and Rb repression and hence is a surrogate marker for oncogenic HPV infection. 25, 32 To be indicative of oncogenic HPV infection in OPSCC, IHC should show nuclear and cytoplasmic reaction to p16 in 70% or more of the cancer cells. 32, 35, 36 Immunohistochemical expression of p16 is a highly sensitive indicator of oncogenic HPV infection in OPSCC and OSCC but has a low positive predictive value of 41.3% in OSCC. 8 In a systematic review and meta-analyses published in 2017, 37 Prigge and colleagues estimated the pooled sensitivity and specificity of p16 IHC in OPSCC as 94% and 83%, respectively. These figures increased to 93% sensitivity and 96% specificity when p16 IHC and HPV DNA PCR were combined. 37 Moreover, it should be noted that p16 expression is not specific to OPSCC-HPV or OSCC but can be used as an affordable and sensitive method to screen for oncogenic HPV infection in OPSCC in combination with histopathological features. 8, 25, 31, 38 Attention should be given to the interpretation and applicability of conclusions of studies regarding HPV and SCC of the oral and oropharyngeal regions. HPV16 is one of the subtypes of HPV implicated in cervical SCC and OPSCC. However, p16 does not HPV, OSCC, and OPSCC: the essentials refer to HPV subtype 16. In some publications, p16 positivity has been confused with and interpreted as HPV16 positivity. However, it should be noted that 'HPV16-positive' merely refers to the presence of HPV16 in a given cancer whereas p16-positive refers to the immunohistochemical expression of p16 protein in the cancer cells.
p16 immunohistochemistry as a standalone determinant of oncogenic HPV status in OSCC and OPSCC
In the vast majority of HNSCC, including OSCC, p16 expression is lost by mutation or deletion. 39, 40 Moreover, p16 can be overexpressed in non-cancerous tissue without oncogenic HPV infection, 41 as well as in HPV-negative OSCC. 8 Therefore, in OSCC, p16 IHC does not accurately reflect oncogenic HPV status and has limited value in recognizing oncogenic HPV infection.
In OPSCC, p16 must be expressed in the nucleus and cytoplasm of 70% or more of the cancer cells for the tumour to be deemed to have a more favourable prognosis and better response to chemoradiation therapy. 25 However, it should be noted that some studies use a cut-off value of 50%, and others take confluence and intensity into account when evaluating p16 immunohistochemical staining. 37 This is an area of potential confusion as the terms 'p16-positive' and 'p16-negative' could be misleading when referring to OPSCCs that express p16 in ≥70% of the cells compared to those that express p16 in <70% of the cells as well as those that do not express p16 at all. 32 Care should be taken to avoid concluding that weak and focal p16 expression in less than 70% of the tumour cells indicates a more favourable prognosis. For obvious reasons, it is more practical to refer to p16 overexpressing tumours as p16-positive, and to those that do not express p16 or show <70% positivity as p16-negative. While the combinations of p16 IHC and HPV DNA ISH or p16 and PCR are both highly sensitive and specific for OPSCC-HPV, E6/E7 mRNA ISH is considered the current gold standard in identifying oncogenic HPV infection in OPSCC. 25, 34, 37 Predicting outcome and planning therapy in p16-positive OPSCC and OPSCC-HPV OPSCC with 70% or more of the cancer cells showing nuclear and cytoplasmic p16-positivity, using IHC ( Figure 3 ) has a better prognosis than p16-negative OPSCC. 32, 35, 36 The 5-year overall survival rates of patients with OPSCC is 45-50% in HPV-negative tumours as opposed to 75-80% in HPV-positive tumours, independent of the mode of treatment. 26 Studies, including one carried out in New Zealand, have also shown that patients with OPSCC-HPV have a more favourable prognosis than those with HPVnegative OPSCC. 18, 42 However, survival is reduced in proportion to tobacco consumption. 26 A systematic review of 18 studies has shown that p16 protein expression is correlated with better prognosis in OPSCC. 36 So far, p16 status has not shown a significant difference with regard to distant metastases in OPSCC. 43 In 2010, Ang et al. categorized patients with OPSCC into three prognostic groups according to HPV status, smoking history, tumour size, and nodal status. 26 The first prognostic group has the best 3-year survival rate (93%) and includes patients with OPSCC-HPV and a smoking history of 10 pack years or less. This group also includes patients with OPSCC-HPV, a smoking history of >10 pack years, and a nodal status of N0-N2a. The second prognostic group has a 71% 3-year survival rate and includes patients with OPSCC-HPV, a smoking history of >10 pack years, and a nodal status of N2b-N3. This group also includes patients with HPV-negative OPSCC, smoking history of 10 years or less, and a T2-T3 tumour size. The third prognostic group has the worst 3-year survival rate (46%) and includes patients with HPV-negative OPSCC, smoking history of 10 years or less, and a T4 tumour size. This group also includes HPV-negative OPSCC and a smoking history of more than 10 years. 26 Results from this and other studies 26, 44 lead to improved understanding of the behaviour and prognosis of OPSCC-HPV and highlighted the need for a new TNM classification more reflective of the prognostic groups 45 which culminated in changing the TNM classification for OPSCC-HPV as determined by p16 status in the 8th Edition of the TNM Classification of Malignant Tumours. A meta-analysis of 93 randomized clinical trials including a pooled cohort of more than 17 000 patients has shown the benefit of intensity-modulated radiation therapy of 70 Gy over a period of 6-7 weeks with concurrent cisplatin chemotherapy in improving the survival of patients with OPSCC. 47 Another study has shown that cetuximab with radiotherapy resulted in a better outcome of patients with both HPV-and p16-negative OPSCC. 48 Based on the high percentage and severity of complications -primarily dysphagia, and due to the more favourable prognosis of OPSCC-HPV and p16-positive OPSCC, several groups started conducting treatment de-escalation and modification trials in patients with OPSCC in an attempt to reduce these side effects and at least partially improve the quality of life of these patients. 49 While OPSCC-HPV and p16 overexpressing OPSCC have a more favourable prognosis, reduction in treatment intensity or tailoring the treatment modality of OPSCC based on HPV or p16 status remains an issue of debate and a number of clinical trials. 49 To date, there are no consensus guidelines on the best treatment strategies for OPSCC-HPV.
CONCLUSION
There is a recent increase in the incidence of OPSCC-HPV, particularly in males. Oncogenic HPV infection plays a limited role in OSCC while it plays a major role in OPSCC. IHC for p16 is only useful in OPSCC and is of limited value in OSCC. Regardless of HPV status, immunohistochemical expression of p16 should be present in ≥70% of the tumour cells for a tumour to be deemed to have a more favourable prognosis. OPSCC-HPV also have a more favourable prognosis but the status for oncogenic HPV infection is best determined by using a combination of methods, preferably including mRNA ISH. Oral healthcare professionals are in an excellent position to screen for and detect OSCC and OPSCC, and the importance of comprehensive and thorough intra-and extra-oral examination cannot be over-emphasized for early detection of OPSCC.
